The consumption of medicines in the Nordic countries 1999-2003 by Paakkari, Pirkko & Voipio, Tinna
Ledare
Läkemedelsanvändning
Naturläkemedel
Medicintekniska produkter
Läkemedel för djur
Editorial
Drug use
Medical devices
38
39
42
44
47
51
52
54
57
58
61
65
67
Egenvårdsläkemedel – en del av en ansvarsfull hälsovård
Hannes Wahlroos
Nytt vaccinationsprogram i Finland från årskiftet
Satu Rapola
Oklarheter i uppföljningsstudier
Esko Nuotto
Läkemedelskonsumtionen i de nordiska länderna 1999–2003
Pirkko Paakkari | Tinna Voipio
Fiskolja och fiskleverolja 
Anna-Liisa Enkovaara | Sari Koski
Rapport över endoproteser 2002–2003 klar
Juha Nevalainen | Petri Pommelin
Komplikationer vid valpsjukevaccinering av pinschrar
Minna Leppänen
Biverkningar av immunologiska läkemedel för djur 2003
Tita-Maria Saukko | Kristina Lehmann
Self medication – part of responsible health care
Hannes Wahlroos
The vaccination programme as redesigned in Finland
from the beginning of the year
Satu Rapola
The consumption of medicines in the Nordic 
countries 1999–2003
Pirkko Paakkari | Tinna Voipio
Report 2002–2003 on endoprostheses completed
Juha Nevalainen | Petri Pommelin
TABU 1.2005
12. vuosikerta
12 årgången
12th Annual volume
In English
På svenska
Lääkelaitoksen päätöksiä
57 1.2005 TABU
HANNES WAHLROOS Editorial
Director General, Professor
National Agency for Medicines
In English
The basic truth expressed by Paracelsus about 500 years
ago about the difference between a poison and a medici-
ne is still valid. Ultimately, all substances are toxic if the
dose is sufficiently high. Then again, even a toxic subs-
tance could be a medicine if the dose is right.
The tendency which began in developed and in-
dustrialised countries at the start of the 1990s, to chan-
ge the classification for the supply of medicinal products
from a prescription only medicine to a self-medication
product, appears still to be continuing. For a while, the
general impression was that the therapeutic indications
and medicines appropriate for self medication had been
weeded out. The legal status of simvastatin, a well-
known and widely used anti-cholesterol agent, as a
prescription-only drug was nevertheless abolished last
year in the UK with certain restrictions. This example,
and the ongoing discussion in Europe about new possib-
le self-medication indications (e.g. depression, diabetes,
gout, hypertension, migraine and psoriasis), show that
self-medication products have at least in some countries
become part of the means to fulfil the political objecti-
ves concerning health.
Consumers and patients have been transformed from
passive and ignorant healthcare targets to interest
groups which emphasise the empowerment, the oppor-
tunity to exert influence and the right of choice of the
individual. A similar effect is exerted by a chronic shor-
tage of financing of the health care system in many
countries, image advertising of medicines, and the in-
creased media attention given to various health themes.
Society is under the threat of becoming medicalised.
This may lead to the excessive consumption of medici-
nes and to harmful effects. The consumption of medici-
nes in Finland (DDD/1,000 inhabitants/day) has in-
creased during the first years of 2000 to become the 
highest in the Nordic countries.1 
In these circumstances, calm judgement is required
from the authorities who decide on the legal status of
medicines, in order that the observations of Paracelsus
and modern day pharmacologists should not be disre-
garded in respect to the protection of the safe use of me-
dicines and the promotion of public health. When tal-
king about self-medication products, we forget that it
was only a little while ago that they were prescription-
only medicines, and that their long lists of adverse ef-
fects, warnings, contraindications and interactions have
remained unchanged. A medicinal substance given the
status of a self-medication product (e.g. terfenadine)
may even become re-classified  to prescription-only me-
dicines, followed by total removal from sale due to ad-
verse effects that have occurred in its use.
A medicine does not become safer to use once the
status of self-medication is granted. With certain
restrictions, its sale and use without a prescription may
nevertheless be approved. The approval is made easier
by ensuring professional pharmaceutical counselling as-
sociated with the purchase. The decision  for self-medi-
cation status may also be enclosed with a provision  to
the marketing authorisation holder to supply the phar-
macies  background material in support of the counsel-
ling they are providing. This was done in Finland in
2002 with regard to an oral contraceptive for postcoital
pregnancy prevention.
With regard to the access to self-medication pro-
ducts, consumers and patients of the EU countries are
not equally placed but are very much dependent on in
which country they are domiciled. The prescription clas-
sification of anti-inflammatory analgesics (ketoprofen,
naproxen) and agents for the treatment of gastric hyper-
acidity (H2 blockers, omeprazole), for example, varies
from country to country. The EU Directive of 1992 on
prescription classification has not markedly increased
uniformity among the countries.
An EU regulation will come into effect October this
year and make centralised decisions on self-medication
status within the entire EU possible. In this case the pro-
duct should constitute a significant innovation or the
decision should be in the interests of patients at Com-
munity level. The differences among the EU countries
are beginning slowly but surely to diminish. Another
matter entirely is the fact that there is no regulation at
Community level of retail outlets for self-medication
products within the EU. The issue falls within the natio-
nal competence. The principal rule in Europe is the sale
of medicines via pharmacies.
In addition to the monitoring of the safety of medici-
nes, the classification of legal status also involves a wi-
der view on the health policy and change in the society.
Citizens are expected to take responsibility for the treat-
ment of their illnesses and the associated symptoms.
With a changing environment, the ‘gate keeper’ should
be able to adjust the decisions on self medication to the
new circumstances. Finland is neither the first, nor the
last, country to make these decisions. An essential con-
straint on the increased and sensible use of self-medica-
tion products is the operation of pharmacies on the pro-
fessional premises supporting the general health policy.
The situation would become different if the sale of me-
dicines were to be entrusted to the hands of non-profes-
sionals and to be directed by competition.
1
Medicines Consumption in the Nordic Countries
1999–2003. NOMESCO 72:2004 (www.nom-nos.dk).
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The aim of the new vaccination
programme is to provide the popula-
tion with the maximum possible co-
ver through vaccines against preven-
table contagious diseases. The need
for a reform in the vaccination
programme is influenced by changes
in the epidemiology of contagious
diseases, the introduction of impro-
ved vaccines on to the market, and
the adverse effects associated with
vaccines.
During 2002 and 2003 changes
were made in the national vaccina-
tion programme, which had remai-
ned unchanged for almost a decade.
Target groups for the influenza
vaccine were extended in the au-
tumn of 2002 so that, besides the in-
dividuals in the category of conven-
tional medical risk groups, the re-
commendation to vaccinate would
also include all Finns of 65 years of
age and older. The booster  vaccina-
tion against diphtheria-tetanus-per-
tussis (dtap, ap = acellular pertussis)
given to children of pre-school age
was added to the vaccination
programme at the beginning of
2003. Polio vaccinations (inactivated
polio vaccine, IPV) at the ages of 11
and 16–18 were abandoned at the
same time, because adequate pro-
tective immunity in Finland is provi-
ded by the vaccination programme
consisting of four injections of the
polio vaccine at pre-school age. Ad-
ditional booster injections are only
required in exceptional cases.
Planning and decision-making
in the vaccination programme 
The Ministry of Social Affairs and
Health (STM) is in charge of the ge-
neral planning, guidelines and moni-
toring of the efforts involved in the
prevention of communicable dise-
ases. The actual vaccination
programme is also decided upon at
the Ministry, where the expert body
on the prevention of transmissible
disease is known as the Advisory
Board on Communicable Diseases.
The National Public Health Institute
(KTL) is the expert institution invol-
ved. The national vaccination expert
group, the vaccination recommenda-
tion working group of the KTL, and
the various vaccine expert groups,
are the experts who support the de-
cision-making process concerned in
the vaccination programme. The
municipalities are responsible for the
practical arrangements surrounding
the vaccinations 
In the design of a general vacci-
nation programme consideration
needs to be given to the importance
of the preventable disease from the
public health point of view, the seve-
rity of the disease and the risk of
contracting the disease in various
age groups, the maturity of immune
response of the individual being
vaccinated, the efficacy of the vacci-
ne, and any adverse effects from the
viewpoint of both the individual and
the society, including the operational
and economical perspectives of
health care.
The design of the national vacci-
nation programme is always the re-
sult of compromise. The aim is to
reach an adequate level of protect-
ion as early as possible and with as
low doses of vaccine and as few ad-
verse effects as possible. The decree
of the STM on vaccinations and
screening for communicable diseases
during pregnancy provides  the gui-
delines for vaccines associated sche-
dules beginning from 1.1.2005 (Tab-
le 1 and 2) 
Vaccinations for adults
All adults should make sure that
they have received the cover of at
least three tetanus, diphtheria and
polio vaccinations. All adults should
also be covered for measles, rubella
and mumps either by having had the
disease or by two MPR vaccine in-
jections. If the vaccination cover in
an adult is found to be inadequate
as far as these vaccinations are
concerned, the cover should be
supplemented. Thereafter, a dT
booster vaccination against diphthe-
ria and tetanus should be given eve-
The vaccination programme as redesigned in 
Finland from the beginning of the year
SATU RAPOLA
Dr.Med.Sc., Specialist in Public Health Medicine
Department of Vaccines
National Public Health Institute (KTL)
With the vaccines used in the redesigned vaccination programme, Finnish children will, as before, be
protected against severe infections caused by tuberculosis, diphtheria, tetanus, whooping cough, measles,
mumps, rubella, polio and Haemophilus influenzae type b (Hib). Owing to the new combination vac-
cines the number of vaccinations required for good protection had been reduced considerably. With the
introduction of the new vaccine products adverse effects are also expected to be reduced.
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ry 10 years. A booster vaccination
against polio (IPV) is required only
in special circumstances.
Vaccinations for special
groups
Hepatitis A and hepatitis B 
vaccinations
Individuals at increased risk of con-
tracting hepatitis A or B due to their
living circumstances are given hepa-
titis vaccinations in accordance with
the indications supplied by the KTL.
Influenza vaccinations
Such special groups of the popula-
tion as are at a considerable health
risk imposed by influenza, are vacci-
nated against influenza every year
before the start of the epidemic pe-
riod. The KTL announces the vacci-
nes which are to be used each year,
including the vaccination indica-
tions, and is in charge of the distri-
bution of influenza vaccines to the
health centres in Finland. In autumn
2002 all Finns of 65 years of age
and over were included in the
groups receiving vaccination.
The recommendation also covers
children of six months of age and
over, who belong to medical risk
groups, and who have no contrain-
dications for vaccination. One dose
of injection is usually adequate in
the annual vaccinations. If the child
is under the age of nine and has not
been given an influenza vaccination
before, one dose of the vaccine does
not necessarily provide adequate co-
ver. It is recommended that such
children be given another equal dose
about six months after the first one.
A Finnish study published in au-
tumn 2004 (1) reviewed the burden
of disease caused by influenza in
children under the age of 13 during
two periods of influenza, 2000–2001
and 2001–2002. In this study, the
parents were advised to bring their
child to the investigation clinic if fe-
ver or respiratory symptoms occur-
red. During the visit to the clinic a
nasopharyngeal sample was taken
for a virus culture. A total of 372
influenza episodes were documented
during the study. The annual inci-
dence of influenza in children under
the age of three was 179/1,000, in
children of 3–6 years of age it was
175/1,000 and in children of 7 years
of age and over it was 142/1,000.
The most common complication as-
sociated with influenza was otitis
with an almost 40% incidence in
children under the age of three. This
is the rate of incidence of otitis in
small children in association with
any upper respiratory virus in-
fection. Antibiotic treatment was
prescribed for various reasons in a
total of 42% of the under three-
year-olds.
The study indicated that especial-
ly influenza in the under three-year-
olds with associated complications,
medical treatment, and the parents'
absence from work to care for their
child, caused a significant burden
from the disease on the children and
their families. One of the conclu-
sions the researchers drew was that
vaccinating this age group against
influenza may be beneficial. 
At its meeting in November the
national vaccination expert group
(KRAR) discussed the influenza
vaccination of small children in the
light of the above information. The
expert group suggests that the KTL
summons a meeting of a broadly ba-
sed working group to review the si-
tuation of influenza vaccinations for
children, hoping for urgent dealing
with the issue in the working group.
The expert group (KRAR) is
expecting a review of the working
group and does not consider boos-
ting the influenza vaccinations of
children with a special campaign
prior to the review to be necessary.
Table 1. Vaccines used in the general vaccination programme: (situation February 2005)
Abbreviation Vaccine
BCG Tuberculosis vaccine (Bacillus Calmette-Guerin), BCG Vaccine SSI
DTaP-IPV-Hib diphtheria = D, tetanus = T, acellular pertussis = aP, polio (IPV) and Haemophilus influenzae type b 
(Hib) vaccin, Pentavac 
DTaP-IPV diphtheria (D), tetanus (T), acellular pertussis (aP) and polio (IPV) vaccine, Tetravac
dtap diphtheria (d), tetanus (t) and acellular pertussis (ap) vaccine, Boostrix
DT diphtheria (D)- and tetanus (T) -vaccine
dT diphtheria (d)- and tetanus (T) vaccine, diTeBooster 
Hib Haemophilus influenzae type b (Hib) vaccine, Hiberix
IPV polio vaccine containing inactivated viruses of type 1, 2 and 3, Imovax Polio
MPR measles (M), parotitis/mumps (P) and rubella (R) vaccine, MMR II
HAV hepatitis A vaccine, Havrix
HBV hepatitis B vaccine, Engerix-B
HAV-HBV hepatitis A and hepatitis B vaccine, Twinrix
influenza influenza vaccine
The amount of antigen in the vaccines is indicated as follows:
D, T, P high amount of antigen
d, t, p low amount of antigen
Table 2. Vaccinations for children and
adolescents
Vaccine Recommended age
BCG < 1 week
DTaP-IPV-Hib 3 months
DTaP-IPV-Hib 5 months
DTaP-IPV-Hib 12 months
MPR I 14–18 months
DTaP-IPV 4 years
MPR II 6 years
dtap 14–15 years
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Transition period
Vaccinations introduced before 2005
are to be continued by special guide-
lines. These guidelines for the transi-
tion period will guarantee an equal
basic cover for all children irres-
pective of the stage at which they
are in the vaccination programme at
the beginning of 2005. Vaccinations
initiated before that will be supple-
mented with new vaccines from the
beginning of 2005. This will dimi-
nish the use of individual vaccines.
Vaccination records
The forms for vaccination and the
personalised health cards used at
health care centres have been rede-
signed. Health care centres should
take care to update their electronic
data systems.
Vaccinations administered will be
recorded in the individual's health
and patient records, either in the
adult or child vaccination forms or
in the electronic health data system.
Besides showing the personal data of
the individual, the recorded data
should show the date, trade name of
vaccine and batch number of the
vaccine including the site and route
of administration. These details are
necessary, for example, for studying
individual adverse reactions and po-
pulation vaccination cover. It is also
recommended that vaccination de-
tails be included in the adult health
card or national vaccination card, or
both. Similarly, details of children's
vaccinations are included in the
child's own health card which is in
the charge of its parents.
Vaccination programme
accomplished
Vaccinations have been a routine for
decades in Finnish families and
health care centres. Prior to school
age, the children are given a pro-
tection against nine severe diseases.
Polio, measles, mumps and rubella,
which are covered by the general
vaccination programme, have alrea-
dy been eradicated in Finland. Tu-
berculosis, diphtheria, tetanus and
severe diseases caused by  Haemo-
philus spp. have almost totally di-
sappeared. Whooping cough has
occurred, but significantly less fre-
quently compared with the period
prior to the vaccination programme.
This good outcome is the result of
the extensive use of effective vacci-
nes in the country. Health care cent-
re system which operates well makes
vaccines available to all families; at
least 93% of the children receive all
the vaccinations in accordance with
the Finnish vaccination programme.
Future challenges
Throughout the years, the attitude
towards vaccinations in Finland has
been mainly positive. Obtaining vo-
luntary vaccinations has not, howe-
ver, always been quite that clear. Pa-
rents want ever more detailed infor-
mation about the vaccines on offer
to their children and about the alter-
natives available. There is plenty of
information on offer about vaccina-
tions, but the quality of information
varies greatly and the sources are al-
so very varied. Use of the Internet
has increased the availability of in-
formation to all citizens, and deba-
tes about vaccinations are carried
out in e-mail groups. Knowledge
about vaccinations among citizens
can be increased and fears and
wrong notions associated with
vaccinations diminished by provi-
ding appropriate information. All
doctors and health care professio-
nals working in outpatient care
should therefore be familiar with the
vaccines of the general vaccination
programme, their benefits and dis-
advantages. 
Vaccines other than those inclu-
ded in the general vaccination
programme are also given on health
care centre appointments and at pri-
vate doctors' offices. New vaccines,
the inclusion of which in the general
vaccination programme is not self-
evident, have been and are being int-
roduced on to the market. Boosting
the vaccinations given in childhood
and adolescence is important in
adulthood. 
In addition to the challenges im-
posed by the general vaccination
programme, vaccination for travel-
lers is also a big challenge to those
involved in vaccination work, as
long-distance travellers and those
working abroad often need special
vaccines. Those carrying out vacci-
nations nowadays are therefore
expected to master a quantity of
such information on vaccination
which previously belonged to the
domain of only a few experts.
1 Heikkinen T, Silvennoinen H, Peltola
V, Ziegler T, Vainionpaa R, Vuorinen T,
Kainulainen L, Puhakka T, Jartti T,
Toikka P, Lehtinen P, Routi T, Juven T.
Burden of influenza in children in the
community. J Infect Dis. 2004;190:
1369-73. Epub 2004 Sep 15.
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The consumption of medicines mea-
sured in defined daily doses
(DDD/1,000 inhabitants/day) incre-
ased steadily in all the Nordic
countries. The increased consump-
tion is partly a result of the ageing
population, as the use of medicines
increases with age. Previously non-
existent medical treatment for dise-
ases, such as Alzheimer’s disease and
multiple sclerosis, have also been
introduced in recent years. The
increasing amount of money spent on
medicines is mostly due to previous
medicines being replaced by more re-
cent and more expensive ones, which
is especially shown in the increased
medical costs involved in the treat-
ment of psychoses and asthma.
Attempts have been made to re-
duce the increasing costs of medici-
nes by the introduction of  generic
substitution in all countries. Generic
substitution together with the simul-
taneous termination of patent pro-
tection, and parallel imports of cer-
tain important medicines, slowed
down the increasing costs at least
temporarily. This was most promi-
nently exhibited by the sales of anta-
cids, which actually dropped by over
20% in Sweden between 1999 and
2003.
A small selection of self-medica-
tion products was released for sale
outside pharmacies in Denmark in
2001 and in Norway in 2003. This
did not result in any significant
changes in consumption. According
to a Danish review, only about 15%
of these particular products were
sold in outlets other than pharma-
cies.
Medicines most frequently
used
The most frequently used medicine
in the Nordic countries was the low-
dose acetylsalicylic acid indicated
for the prevention of myocardial in-
farction and used by 5–10% of the
population. The list of the ten top
medicines in all the countries inclu-
ded furosemide, simvastatin and/or
atorvastatin, and enalapril and/or
ramipril in Sweden, Finland and
Denmark. Among analgesics, para-
cetamol topped the list of most fre-
quently sold medicines in Denmark,
Sweden and Norway, and ibuprofen
in Finland and Iceland. Among hyp-
notics and sedatives, zopiclone was
included on the list of most fre-
quently sold medicines in Iceland,
Norway and Finland; another hyp-
notic included on list in Finland was
temazepam.
The proportion of the ten most
frequently sold medicinal substances
with the consumption expressed as
daily doses was 49% in Norway,
and 23–28% in the other Nordic
countries. Their share in the total
cost of medicines was distinctly lo-
wer, 7–12%, i.e. the medicines most
frequently used are mainly old, rela-
tively low-cost products.
The medicines generating the
highest costs of all in all the count-
ries included proton pump inhibitors
used for gastric ulcers, indigestion
and reflux disease, and lipid-lowe-
ring agents. Measured by their the-
rapeutic indications, the majority of
medicines used were for the treat-
ment of cardiovascular diseases,
pain and psychiatric disorders.
Cardiovascular medicines
The consumption of cardiovascular
drugs was rapidly further increased,
which was mainly a result of the
increased use of more recent drugs
with an effect on the renin-angioten-
sin system, and cholesterol-lowering
drugs. The biggest consumption of
cholesterol-lowering drugs was seen
PIRKKO PAAKKARI
Senior Medical Officer
TINNA VOIPIO
Researcher
National Agency for Medicines
The consumption of medicines in the Nordic
countries 1999–2003
The Nordic Medico-Statistical Committee (Nomesco) has published drug statistics on the sales of the
most important groups of drugs in the Nordic countries during 1999-2003. A few gleanings from the
booklet Medicines Consumption in the Nordic Countries are presented below.
In English
Drug use
The consumption of medicines is presented as DDD, defined daily dose, in relation to the population and time period
(DDD/1,000 inhabitants/day). The proportion of population that used the particular medicine daily as a daily dose is presen-
ted in promilles. The DDD is a unit used in international drug statistics based on the average adult daily dose  for the main
indication of the drug. For ease of reading, DDD/1,000 inhabitants/day has in this text been abbreviated to DID. 
The figures in the text refer to the year 2003. Data from Faroes, Greenland and Åland is included the figures only.
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in Norway, followed by Finland,
whereas Denmark had the lowest
consumption of all (Fig. 1).
The biggest difference in the
group of antihypertensives was seen
in the consumption of diuretics. The
highest use was seen in Denmark
(108 DID), where the use of thiazi-
des alone accounted for almost half
of the consumption, the lowest in
Norway (42 DID). In Finland the
use of thiazides alone was insignifi-
cant (5 DID), whereas the combined
use of thiazides and potassium spa-
ring diuretics in Finland (23 DID)
was double the figure it reached in
Sweden (12 DID) and about four ti-
mes that in Denmark and Norway
(6–7 DID).
The consumption of beta-
blockers was highest in Finland (66
DID) and lowest in Denmark (27
DID). The level of use of calcium
channel blockers did not vary signi-
ficantly among the different count-
ries (31–45 DID).
The level of use of substances
with an effect on the renin-angioten-
sin system was highest in Finland
(108 DID) and Norway (96 DID),
whereas it was lowest in Denmark
(74 DID). Differences within the
group were seen: combination pro-
ducts of ACE inhibitors and diure-
tics were used to a higher extent in
Finland (14 DID) than in the other
countries (Sweden 2.5, Denmark
3.5, Norway 7.5 DID) whereas the
use of angiotensin II antagonists was
more common in Norway and Swe-
den (20–27 DID) compared with
Finland (19 DID).
There was a two- to four-fold
increase in the consumption of sta-
tins in all of the countries between
1999 and 2003.  The consumption
in Norway in 2003 was 98 DID,
Sweden, Iceland and Finland 64–66
DID and Denmark 45 DID.
Hormones
The consumption of the contracepti-
ve pill decreased slightly in Finland
and Sweden, but it increased in the
other Nordic countries. The use of
products for hormone replacement
therapy decreased in Sweden,
Norway and Iceland beginning from
1999, also followed by a decrease in
Denmark and Finland in 2003. 
Antidepressants and 
antipsychotics
The consumption of antidepressants
continued to grow in all of the
countries. The highest consumption
of drugs of this group was seen in
Iceland, and the lowest in Finland
(Fig.). Use of serotonin selective
drugs has increased in particular.
This group contains less costly ap-
propriate alternatives, and the con-
sumption in the group measured in
money increased to a lesser degree
(35% in Finland) than when measu-
red in daily doses (45%).
Treatment of psychosis has mo-
ved on to using relatively recent and
more expensive drugs than before.
In all the Nordic countries combined
the use of antipsychotics increased
only slightly, but their consumption
Fig. 1. Consumption of drugs for cardiovascular diseases 1990–2003
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measured in money increased sharp-
ly by 62–138% depending on the
country, between 1999 and 2003
(109% in Finland).
Antiasthmatics
The consumption of antiasthmatics
has not increased in recent years, in
fact, it is shown to have dropped in
most of the countries instead (Fig.
3). This is misleading,  and caused
by statistics which show an increase
in the use of combination products.
Combination products have an es-
tablished daily dose, and when both
the active agents are taken separate-
ly, the same amount of medicine is
calculated as two daily doses. Com-
bination products should only be
used in situations where it has not
been possible to control the symp-
toms with an inhaled corticosteroid
and beta-2 agonists, administered as
necessary, but this guideline does
not appear to be adhered to and the
use of combination products has
increased rapidly, especially in
Norway, Iceland and Finland. As a
result, the treatment for asthma has
become markedly more expensive in
all the Nordic countries. The sales
of drugs of the ATC Code R03A
(beta-agonists and beta-agonist-cor-
ticosteroid combinations) measured
in money increased in between 1999
and 2003 by 62% at the least (Den-
mark) and by 165% at the most
(Iceland). In Finland, the sales in-
creased by 121%.
Conclusion
The use of medicines in the Nordic
countries is relatively uniform, inclu-
ding the challenges due to increased
consumption faced by those respon-
sible for the attempts to restrict the
spiralling costs of medicines. Nevert-
heless, differences can also be discer-
ned in the consumption. The lowest
consumption of medicines is found
in Denmark, whereas the biggest
users are Sweden and Finland if all
the defined daily doses are combi-
ned. However, the differences vary,
and consequently, the consumption
of one group of drugs may in any
one country be the highest of all and
that of another group the lowest.
Fig. 1. Consumption of antidepressants 1990–2003
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The booklet Medicines Consump-
tion in the Nordic countries can
be ordered by the website of the
Nordic Medico-Statistical Commit-
tee www.nom.nos.dk  
The publication can also be
downloaded as a PDF file from
the website.
The booklet Finnish Statistics on
Medicines can be ordered by 
e-mail: salesstatistics@nam.fi  
Fig. 3. Consumption of antiasthmatics 1990–2003
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The recording of endoprosthetic sur-
gical procedures has a long tradition
in Finland. National data have been
inserted in the same register ever
since 1980, which is notable as a
long uninterrupted period as far as
the history of registers goes. It has
produced valuable information for
many and various purposes. By the
end of 2003 the data on endoprost-
heses in the implant register maintai-
ned by the National Agency for Me-
dicines consisted of the monitoring
of a total of 180,446 endoprosthe-
ses. There are well over a million
follow-up years.
The implant register has been
maintained by the National Agency
for Medicines since 1995, with the
responsibility for supervising the
permanent implants in humans and
promoting the safe use of healthcare
equipment such as implants.
Has the implant register had
any impact in Finland?
There has been a nearly ten-fold
increase in the use of endoprostheses
in Finland during the past 20 years.
However, the number of these ope-
rations does not yet correspond to
the need for surgery among the po-
pulation. For hip and knee joint en-
doprostheses a hundred operations
in one year in a population of
100,000 was previously considered
a good achievement. The require-
ment for surgery is suggested as
being four-fold nowadays, making
an approximate estimate. Several
municipalities in Finland already
match this number of endoprosthe-
sis operations in fact, owing to the
high proportion of elderly citizens in
these municipalities. The effect the
publication of the number of opera-
tions has had on the decisions of
municipalities to buy surgical proce-
dures for their inhabitants has not
been studied by the National Agency
for Medicines. Nevertheless, it may
be that the publication of the num-
ber of procedures promotes a more
equal treatment of citizens in the va-
rious parts of the country; as the ci-
tizens may compare the numbers of
operations in their own municipality
with that in the neighbouring muni-
cipality, thereby putting pressure on
decisions about healthcare resources.
Has the performance of endo-
prosthesis surgery improved?
Suddenly in the mid-1990s Finland
had exceptionally high numbers of
reoperations on endoprosthetic hip
joint replacements. In an attempt to
rectify the situation, the National
Agency for Medicines increased the
output of information about the
implant register. In fact, the publica-
tion of data met with strong criti-
cism from a section of the members
of the orthopaedic profession. This
has, however, since abated due to
improved results. But is the use of
endoprostheses undergoing a change
of practice? In 2003, the ten most
popular models of endoprostheses in
hip joint surgery covered 85% of
the total use. This is likely to be a
consequence of the publication of
the data on performance, especially
in the endoprosthesis registers in the
Nordic countries. Comprehensive re-
search data are available on almost
all models of the majority of en-
doprotheses in use nowadays.
Hip joint endoprosthesis surgery
in the whole country in 1999 resul-
ted in reoperation in 24.6% of the
cases. Nowadays the number of reo-
perations exceeds 20% of all hip
joint endoprostheses in the areas of
only six hospital districts. The main
explanation even in these cases ap-
pears to be the insignificant increase
in the number of first operations.
The success rates of certain mo-
dels of endoprosthesis are very good
in the whole country, both for hip
and knee joints. Even the results on
the unselected material in the count-
ry stand up to comparison at least
with the series of results published
world-wide. This promising develop-
ment is likely to have been inf-
luenced by the training provided by
manufacturers, importers and pro-
fessional organisations.
Endoprosthesis procedures are
gradually moving to larger units.
From the viewpoint of the supervi-
sory authority on the safety of medi-
cal devices, this development is no
doubt greeted with joy. The Mi-
nistry of Social Affairs and Health
has expressed its preparedness to sti-
pulate recommendations for mini-
mum numbers of operations in the
endoprosthesis field within the pub-
lic health care services. The fa-
vourable development in perfor-
mance is the result of several insepa-
rable components, but the perfor-
mance of larger surgical units is like-
ly to be superior, at least in the long
term. The larger units have better
opportunities for follow-up and re-
search.
New significant happenings in
the endoprosthesis field in the next
few years will take place in the area
of newly introduced or re-introdu-
ced sliding surface materials and the
reintroduction of the coating of
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prostheses. The use of coating mate-
rial for hip joint replacements in
Finland is probably the most exten-
sive in the world in proportion to
the population, as monitored by an
independent register (n = 557). At
present, however, in view of the fact
that the material has been involved
in only one reoperation, it is impos-
sible to draw conclusions about the
long-term success of the procedure.
Finland has an evident obligation to
follow up any developments in this
procedure very carefully and report
the results to the orthopaedic com-
munity.
As the performance of endo-
prosthesis procedures is improving,
the register used in the monitoring
of the performance should also be
made more accurate. From the
viewpoint of the medical devices sa-
fety authority, the most important
project is the identification of the
materials available. A project on an
implant database is nearing its
completion at the National Agency
for Medicines, in which each com-
ponent used will be individually
identified. This is step towards  an
electronic data system. According to
experiments carried out in Finland it
is likely that the electronic system
will occupy a position alongside the
present reporting system without
completely replacing it.
Prior to entering the data in the
register the data will be manually
examined twice by two different
parties to ensure that high reliability
is retained. The data are examined
at the National Agency for Medici-
nes prior to inclusion in the register,
and hospitals are offered the oppor-
tunity to check their own individual
data annually. Some hospitals have
used this opportunity. On inspect-
ion, most of the hospitals have
found that their total data corres-
pond to their own files.
The compilation of recorded da-
ta is not possible without their syste-
matic collection from hospitals. Da-
ta collection is a labour intensive
operation, and the filling of forms
often takes place after the operation
when there is pressure to move on
to the next job. The accuracy of the
information as it stands is worthy of
congratulation, and the compliments
go to all participants in the col-
lection procedure!
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